<DOC>
	<DOCNO>NCT01749137</DOCNO>
	<brief_summary>The purpose study evaluate effect RM-493 mean percent body weight loss , weight loss parameter well Pharmacokinetic ( PK ) profile , ambulatory blood pressure obese patient . The study design evaluate efficacy tolerability single dose RM-493 . The study drug ( RM-493 placebo ) administer subcutaneously blind fashion .</brief_summary>
	<brief_title>Phase 2 Study Evaluate Safety Efficacy Rm-493 Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Be age 18 65 . 2 . Able provide voluntary , write informed consent comprehension aspect protocol , prior study procedure . 3 . In good general health , without significant medical history , physical examination finding , clinical laboratory abnormality . 4 . Body Mass Index : 3550 Kg/m² , inclusive . It plan approximately 20 patient BMI ≥ 40 Kg/m² . 5 . Stable body weight ( +/ 5 Kg ) previous 6 month . 6 . Blood pressure ( &lt; 140/90 mmHg ) ; may include stable dose ( ≥ 30 day use ) two antihypertensive medication achieve control intend remain stable dose protocol . 7 . Willingness demonstrate ability self administer study medication subcutaneously via infusion pump placebo practice period . 8 . Willing maintain healthy diet exercise regime throughout study recommend counsel study start . 9 . Females childbearing potential must agree abstinent else use two follow medically acceptable form contraception Screening Period completion study treatment : hormonal , condom spermicidal jelly , diaphragm cervical cap spermicidal jelly , IUD . Hormonal contraception must start least 3 month prior screen . A female whose male partner vasectomy must agree use one additional form medically acceptable contraception . Patients must agree practice birth control method 30 day completion study treatment safety precaution . 10 . Females nonchildbearing potential , define surgically sterile ( status post hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) postmenopausal least 12 month ( confirm screen FSH level postmenopausal range ) , require contraception study . 11 . Males female partner childbearing potential must agree use two medically acceptable form contraception describe , one two form condom spermicide , Screening Period 90 day completion study treatment . Males female partner childbearing potential surgically sterile ( status post vasectomy ) must agree use condom spermicide period time . 1 . Fasting blood glucose &gt; 140 mg/dL . 2 . HbA1c ≥6.5 % . 3 . TSH level outside normal range . 4 . Creatinine &gt; 1.5 time upper limit normal . 5 . Liver function test &gt; 2 time upper limit normal . 6 . Active history significant medical condition include renal , hepatic , pulmonary , gastrointestinal , cardiovascular , genitourinary , endocrine , immunologic , metabolic , neurologic hematological disease . 7 . Patients history follow : 1 . Uncontrolled hypertension ; 2 . Diabetes require medical treatment , presently past ; 3 . Major depressive disorder within last 2 year ; 4 . Any lifetime history suicide attempt ; 5 . Any suicidal behavior last month ; 6 . Other severe psychiatric disorder ( e.g . schizophrenia , bipolar disorder , severe eat disorder include bulimia ) . 8 . A PHQ9 score ≥15 . 9 . Any suicidal ideation type 4 5 CSSRS . 10 . Prior bariatric surgery . 11 . Treated anorectic agent drug anorexia frequent side event . 12 . Taking 3 antihypertensive medication . 13 . Acute illness history illness , opinion Investigator , could pose threat harm patient obscure interpretation laboratory test result interpretation study data . 14 . History HIV infection . 15 . History significant drug hypersensitivity anaphylaxis . 16 . History hypersensitivity protein ( e.g. , allergy shot ) . 17 . Any clinically significant abnormality screen laboratory determine Investigator . 18 . Abnormal 12lead electrocardiogram ( ECG ) screen predose ( Day 1 ) , except minor deviation deem clinical significance Investigator . QTc must &lt; 450 ms. 19 . Received experimental drug device participate clinical study within 30 day prior dose . 20 . Hospitalization surgery within 3 month prior screen except minor outpatient procedure , plan hospitalization study period . 21 . Poor venous access inability tolerate venipuncture . 22 . Inability attend study visit comply protocol requirement include fast restriction concomitant medication intake . 23 . Participation weight loss program study period , include nutritional supplements/ replacement recommend nutritional counseling provide study start . 24 . Use prescription medication regular basis follow exception : 1 . Contraceptives ( must ≥3 month ) ; 2 . Hormone replacement therapy ( must stable dose ≥3 month ) ; 3 . Antihypertensives ( &lt; 3 medication stable dose ≥ 30 day ) ; 4 . Statins ( dose must ≤ half maximum dose ; must stable dose ≥3 month ) ; 5 . Fibrates ( must stable dose ≥3 month ) ; 6 . Niacin ( must stable dose ≥3 month ) ; 7 . Thyroxin ( stable dose ≥ 30 day ) ; 8 . The last use prescription medication must great 5 halflives specific medication least 14 day prior randomization , whichever longer . 25 . Women pregnant breast feeding . 26 . Previously randomize dose study previously expose RM493 . 27 . History alcohol drug abuse within 5 year Screening Visit . 28 . Any reason , opinion Investigator would confound proper evaluation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Overweight</keyword>
</DOC>